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Articular cartilage injuries in the knee are common, and 
despite 2 decades of intensive research, the treatment remains 
challenging.1,2 Depending on factors such as defect location 
and size, patient age, activity level, comorbidities, and 
defect chronicity, the surgeon can choose from among an 
array of treatment options, including microfracture, scaffold-
supported microfracture, osteochondral autograft and 
allograft transplantation, and autologous chondrocyte 
implantation (ACI)–related techniques.3 The use of cul-
tured autologous chondrocytes for implantation under a 
periosteal membrane (i.e., ACI) as originally proposed by 
Grande et al.4 and clinically applied by Brittberg et al.5 has 
given rise to a large number of related treatments, which 
occasionally are introduced to the clinic with limited pre-
clinical evidence. These treatments are either “second-
generation” ACI techniques using a synthetic membrane as 
a substitute for the periosteum or “third-generation” ACI 
methods using synthetic membranes or biodegradable, 
porous sponge-like scaffolds or gels as carriers for the 
chondrocytes. In addition, modifications of the growth and 
selection of the chondrocytes used in ACI have been intro-
duced into the clinic, including implementation of protocols 
to investigate the chondrogenic potential of cells prior to 
their implantation and matrix-free growth of the cells to 
form spheroids.6-8
A critical question for all cell-based therapies, which 
has not yet been definitively answered, is how the exoge-
nous cells contribute to chondrogenesis: do the cells them-
selves proliferate, retaining their phenotype, and directly 
synthesize the cartilaginous matrix? Or do the exogenous 
cells serve as regulators of endogenous progenitor cell dif-
ferentiation and function? In either of the hypothesized 
cases, the cell density could serve as an important parame-
ter in determining the outcome of the procedure by main-
taining the chondrogenic phenotype and synthesizing 
matrix, which will be discussed later. Relative to the amount 
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Abstract
Cartilage repair techniques have been among the most intensively investigated treatments in orthopedics for the past 
decade, and several different treatment modalities are currently available. Despite the extensive research effort within 
this field, the generation of hyaline cartilage remains a considerable challenge. There are many parameters attendant to 
each of the cartilage repair techniques that can affect the amount and types of reparative tissue generated in the cartilage 
defect, and some of the most fundamental of these parameters have yet to be fully investigated. For procedures in which 
in vitro–cultured autologous chondrocytes are implanted under a periosteal or synthetic membrane cover, or seeded onto 
a porous membrane or scaffold, little is known about how the number of cells affects the clinical outcome. Few published 
clinical studies address the cell seeding density that was employed. The principal objective of this review is to provide an 
overview of the cell seeding densities used in cell-based treatments currently available in the clinic for cartilage repair. 
Select preclinical studies that have informed the use of specific cell seeding densities in the clinic are also discussed.
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of research performed within the field of cartilage repair, 
this issue has previously received very little attention.9 
Although the evidence for ACI-related treatments for carti-
lage repair is continuously being debated,10 systematic 
reviews of the clinical outcomes and complications of many 
of these treatments in human trials have been published 
elsewhere and will not be discussed here.11-13
Of the many factors that might affect the outcome of the 
cell-based treatments, one that has received little attention 
is the number of cells injected, or incorporated into a scaf-
fold and implanted, into the defect. The number of cells can 
be provided in terms of cell density by volume, based on the 
estimated articulating surface occupied by the lesion and 
assumed cartilage thickness. At times, the cell density may 
be presented on the basis of the area of the lesion alone as 
judged by the surgeon. Finally, there are times when the 
area density may be based on the surface area within the 
lesion available for cell attachment (e.g., base and walls of 
the defect). The objectives of the present review are to 
address the issues surrounding the criteria for the selection 
of the chondrocyte seeding density for articular cartilage 
repair and to provide an overview of the cell seeding densi-
ties used in commercially available cell-based treatments 
that are currently approved for clinical use in the United 
States and other countries. Data for the latter were obtained 
from the websites or representatives of the companies that 
process the cells. The goal is to provide a basis for the 
informed decision of the number of cells to be used and future 
studies to address these critical unanswered questions.
While the focus of this review is on the number of cells 
per unit area, assessed by the surgeon, that are employed in 
cell-based cartilage repair procedures, it is clear that other 
factors (outside the scope of this review), which can affect 
the “quality” (including phenotype, biosynthetic activity, 
survivability) and homogeneity of the cells being used, are 
also important: the culture medium employed for the cell 
expansion in vitro, including the use of autologous or 
bovine serum and growth factor supplementation; the oxy-
gen concentration; time in culture; and type of tissue culture 
dishware, including bioreactors. The “optimum” cell num-
ber for a specific defect is clearly interrelated with the qual-
ity and homogeneity of the cells. Just as there has been 
relatively little work relating the cell number to the clinical 
outcome, so too have there been few studies relating the 
quality and homogeneity of the cells to effectiveness in 
facilitating cartilage repair.
Clinical Treatments
In the original work of the ACI procedure with periosteal 
cover, Brittberg et al. used an injection of 2.6 to 5.0 × 106 
cells under the periosteal flap in defects with a mean size 
of 3.1 cm2.5 In concordance with this study, subsequent 
investigations using this procedure most often describe an 
indirect seeding density by the number of cells in the 
syringe, when mentioned at all. An average number of cells 
in the defect can then be approximated by the average 
defect size. The calculated seeding density used is gener-
ally close to 1 × 106 cells/cm2. In 2002, Peterson et al. 
reported good or excellent results in 50 of 61 patients 24 
months after surgery and good or excellent results in 51 of 
61 patients after 5 to 11 years.14 Peterson et al. also 
reported the outcome of 58 patients with 2 to 11 years’ 
follow-up in 2003.15 At 24 months’ follow-up, 91% of the 
patients had a good (22/58) or excellent (31/58) outcome. 
In these 2 Swedish studies, 4.5 × 106 cells in 3.4-cm2 
average-sized defects and 5.2 × 106 cells in 5.7-cm2 aver-
age-sized defects were used, respectively.
Since Peterson et al.’s original work, additional related 
products have become available that use chondrocytes. An 
overview of these technologies follows below; the cell 
seeding densities are provided in Table 1. While this refers 
only to the densities at the time of shipment from the manu-
facturer, the subsequent handling before implantation might 
significantly affect the viability and quality of the cells.
Cell Suspensions with Cover
Carticel (Genzyme, Cambridge, MA) is a first-generation 
periosteum-covered autologous chondrocyte product based 
on work by Brittberg and Peterson.5 It has demonstrated its 
efficacy in multiple studies.16-18 To simplify the surgical 
procedure and avoid hypertrophy-related complications, 
the procedure is now performed mostly with a collagen 
patch cover. This approach showed a decrease in hypertrophy-
related reoperations in 101 patients compared to a cohort of 
300 patients who had undergone periosteum-covered 
ACI.19 The finished Carticel (Genzyme) vial contains 
approximately 12 million cells, and 1 vial is provided for 
defects ≤7 cm2, 2 vials for defects 7 to 14 cm2, and 3 vials 
for defects >14 cm2. In a study using a collagen membrane 
as a carrier for Carticel-cultured (Genzyme) cells, cells 
were seeded onto the scaffold in the operation room with 
recommended cell densities as described above.20
The CartiGro (Stryker, Montreux, Switzerland) proce-
dure utilizes cells cultured by CellGenix (Freiburg, 
Germany) in conjunction with a Chondro-Gide (Geistlich 
Biomaterials, Wolhusen, Switzerland) scaffold. Chondro-
Gide (Geistlich Biomaterials) consists of a porcine-derived 
collagen type I/III matrix that is used as a common scaffold 
for cultured chondrocytes in Europe. A vial of up to 12 × 106 
cells is provided to the surgeon to seed a Chondro-Gide 
(Geistlich Biomaterials) matrix of 12 cm2. The company 
recommends a seeding density of 1.0 to 1.5 × 106 cells/cm2, 
although some surgeons tend to use densities up to 3.0 × 106 
cells/cm2 for smaller defects. Because the final product is 
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assembled in the operation room by the surgeon, the density 
might therefore vary according to the defect location, size, 
and previous experiences of the surgeon.
ChondroCelect (TiGenix, Leuven, Belgium) is an autolo-
gous chondrocyte product used in characterized chondrocyte 
implantation (CCI).21-23 It differs from other cell-based thera-
pies through the use of the so-called ChondroCelect (TiGenix) 
score; the cell culture is given a quality score derived from 
several gene markers, and implantation is not recommended 
below a certain threshold. A cell density of 0.8 to 1.0 × 106 
cells/cm2 is used under a periosteal cover. While structural 
regeneration showed by histology was significantly better for 
CCI compared to microfracture, no difference in clinical out-
come was found after 18 months.6 However, after 36-month 
follow-up, the authors found that the clinical outcome using 
CCI was significantly better than by microfracture.24
Scaffold Carriers
BioCart II (ProChon, Ness Ziona, Israel) is a technique that 
uses a fibrin-hyaluronan scaffold (CartiMate) and a fibro-
blast growth factor (FGF) variant to enhance the proliferation 
rate and the chondrogenic potential of chondrocytes. In this 
treatment, approximately 0.5 × 106 cells/cm2 are seeded onto 
the scaffold 3 to 4 days prior to surgery. A preliminary study 
on 8 patients showed an improvement in outcome after 
1-year follow-up, and another study using MRI T2-mapping 
and dGEMRIC has shown relaxation times close to those of 
native cartilage at 15- to 27-month follow-up.25,26
BioSeed-C (Biotissue Technologies, Freiburg, Germany) 
uses a biodegradable polylactate scaffold as a carrier. 
Chondrocytes with a density of 20 × 106 cells/cm3 are 
seeded onto the scaffold, with the dimensions 2 × 3 × 0.2 cm 
corresponding to 4 × 106 cells/cm2. Two- and 4-year follow-up 
results on 79 patients showed a significant improvement 
in International Knee Documentation Committee (IKDC) 
score that was maintained up to 4 years postoperatively.27,28 
Erggelet et al.29 retrospectively compared the use of 
BioSeed-C (Biotissue Technologies) to periosteum-covered 
ACI and concluded that the treatments were equally effec-
tive for focal cartilage defects. Zeifang et al.30 published a 
randomized controlled trial comparing BioSeed-C (Biotissue 
Technologies) to periosteum-covered ACI and found no 
differences in IKDC score, Tegner activity score, and Short 
Form-36 score between the groups at 1 and 2 years’ follow-up. 
They did, however, observe better outcomes in the perios-
teum group in the Lysholm and Gillquist scores.
Hyalograft C (Anika Therapeutics, Bedford, MA) is a 
hyaluronic acid–based scaffold seeded with chondrocytes. 
Marcacci et al. were the first to report the midterm clinical 
outcome using Hyalograft C (Anika Therapeutics) in a mul-
ticenter case series of 141 patients with 2 to 5 years’ follow-
up.31 Patients reported a significant improvement from 
baseline in functional outcome and subjective knee assess-
ment. Gobbi et al. published 2 case series with follow-up 
times from 1 to 5 years.32,33 The first study showed improve-
ment in 29 of 32 patients after 2 years, but their second 
study demonstrated a decline in IKDC score within 2 to 
5 years in 34 patients. Two cohort studies have been pub-
lished comparing Hyalograft C (Anika Therapeutics) to 
microfracture, showing a significantly higher IKDC score 
at 5 years using Hyalograft C (Anika Therapeutics),34 and to 
Table 1. Cell Seeding Densities Used in Available Clinical Treatments
Treatment Name Company Cell density
Cover ChondroCelect TiGenix 0.8-1.0 × 106/cm2
 Carticel Genzyme ≥2.0 × 106/cm2a
 CartiGro CellGenix/Geistlich 1.0-1.5 × 106/cm2
Scaffold carrier BioCart II ProChon 0.5 × 106/cm2
 BioSeed-C Biotissue 4 × 106/cm2
 Hyalograft C Anika N/A
 MACI Genzyme 1 × 106/cm2
 NeoCart Histogenics N/A
 Novocart 3D Tetec 0.5-3.0 × 106/cm2
Gel type Cartipatch TBF Tissue Engineering >10 × 106/mL
 Chondron Sewon CellOnTech 12 × 106/vial
 CaReS Arthro Kinetics N/A
Other Chondrosphere co.don 2-14 × 106/cm2
 deNovo NT Zimmer N/A
 CAIS DePuy Mitek N/A
Note: N/A = not applicable.
aDependent on defect size. Each vial contains 14 million cells. One vial is used for defects 0 to 7 cm2, 2 vials for defects 7 to 14 cm2, and 3 vials for 
defects >14 cm2.
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treatment with a collagen-based scaffold (CaReS), showing 
comparable clinical outcomes after 2 years.35 Additionally, 
2 MRI follow-up studies showed complete filling in 15 of 
23 patients after 2 years and in 26 of 40 patients after a 
minimum of 5 years, respectively.36,37
MACI (Genzyme Europe, Naarden, the Netherlands), or 
matrix-assisted chondrocyte implantation, is often used as a 
general term to refer to any chondrocyte-seeded scaffold 
treatment. MACI (Genzyme Europe) uses a bovine-derived 
collagen type I/III scaffold as a chondrocyte carrier and, 
like many of the other treatments in this review, is not avail-
able in the United States. Chondrocytes are seeded at a den-
sity of 1.0 × 106 cells/cm2 onto the scaffold 4 days prior to 
implantation, and the results have shown that 8 of 11 
patients reported they did “better” or “much better” after 
surgery and that clinical scores showed significantly 
improved outcome after 5 years.38 In a randomized study of 
defects larger than 4 cm2, MACI (Genzyme Europe) pro-
vided significantly better outcomes when compared with 
microfracture.39
NeoCart (Histogenics, Waltham, MA) was used in a 
small series of 8 patients with full-thickness cartilage 
defects in the distal femur.40 Harvested chondrocytes from 
a biopsy were expanded and seeded into a 3-dimensional 
bovine type I collagen honeycomb matrix for culture in a 
bioreactor setting including hydrostatic pressure followed 
by static culturing. They found a significant decrease in 
visual analog scale (VAS) score for pain and that 7 of 
8 patients had improved outcome from baseline on IKDC.
Novocart (Tetec, Reutlingen, Germany) is a culturing 
technique for ACI, while Novocart 3D (Tetec) is a collagen–
chondroitin sulfate scaffold seeded with chondrocytes with 
a density of 0.5 to 3.0 × 106 cells/cm2. Twenty-two patients 
with osteochondral defects (average, 4.8 cm2) due to osteo-
chondritis dissecans (OCD) underwent restoration of the 
bony defect with autologous cylinder bone grafts from the 
iliac crest with concurrent Novocart 3D (Tetec) treatment to 
restore the articular surface. The average follow-up was 
16 months, and patients showed significant improvement 
compared to baseline.41
Gel-Type Carriers
CaReS (Arthro Kinetics, Berlin, Germany) is the combina-
tion of autologous chondrocytes seeded in a 3-dimensional 
collagen type 1 gel (rat tail cartilage). Because cells are 
seeded directly into the gel and are never kept in 2-dimensional 
culture, no cell dedifferentiation occurs. Maus et al. reported 
on the application of this product in 13 patients with OCD 
lesions of the knee, with an average lesion size of 8.1 cm2. 
After an average follow-up of approximately 3 years, 
patients demonstrated significant improvements in pain and 
function. One graft failed, and the patient was treated with 
marrow stimulation.42
Cartipatch (TBF Tissue Engineering, Mions, France) is a 
product in which monolayer-expanded autologous chondro-
cytes are embedded into an agarose-alginate hydrogel at a 
density of at least 10 × 106 cells/cm3. Selmi et al. presented 
the first clinical outcome in a small prospective multicenter 
study on 17 patients with 2-year follow-up.43 The patients 
improved significantly in IKDC score from baseline after 
both 1 and 2 years, and cartilage histology results showed 
predominantly hyaline cartilage in 8 of 13 patients (69%).
For the Chondron (Sewon CellOnTech, Seoul, South 
Korea) treatment, a vial of 12 × 106 cells is provided for 
implantation after mixing with a fibrin gel. Choi et al. 
reported the outcome of a series of 98 patients divided into 
2 groups.7 Based on telephone interviews, they found a sig-
nificant improvement from baseline in patient-reported 
outcome, with the results in the >25-month group being sig-
nificantly better than the 13- to 25-month group.
Other Cell Implantation Treatments
Chondrosphere (co.don, Teltow, Germany) utilizes autolo-
gous chondrocytes grown in the patient’s own serum; cells 
are initially expanded in monolayer and then are transferred 
into a suspension culture.44 During the subsequent 2 weeks, 
the chondrocytes form small (~500-800 μm in diameter) 
spheroids of immature cartilage matrix. These spheroids 
are implanted at a density of approximately 3 × 106 cells/
cm2 without any additional fixation and adhere to the sub-
chondral bone. This approach differs from the above by in 
vitro formation of condensed chondrocyte spheres and 
early matrix formation prior to implantation. A study of 36 
patients followed for 12 months demonstrated significant 
improvements in IKDC, Western Ontario and McMaster 
Universities Arthritis Index (WOMAC), and Lysholm 
scores. Nine patients underwent second-look arthroscopy, 
which showed excellent integration and fill.8
As an alternative to implantation of in vitro–cultured 
chondrocytes, implantation of a morselized autologous car-
tilage biopsy containing both cells and matrix is being inves-
tigated as a 1-step procedure known as Cartilage Autograft 
Implantation System (CAIS, DePuy Mitek, Raynham, 
MA). Cole et al. compared this to microfracture and found 
significantly better clinical outcome at 12 and 24 months 
using CAIS (DePuy Mitek).45
A demonstration of true regeneration of articular carti-
lage has been shown in the fetal lamb.46 The development 
of articular cartilage from the fetal through juvenile to adult 
state is a process that yields several structural and biological 
differences at each state.47 In terms of morphology, a dra-
matic decrease in chondrocyte density is seen throughout 
this maturation.48 A recent approach for cartilage repair, 
deNovo NT (Zimmer, Warsaw, IN), aims at integrating the 
benefits of immature cartilage into a clinical treatment 
modality by using allogenous particulate juvenile cartilage 
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with live cells. The first report on the outcome of 4 patients 
with 2-year follow-up showed improvement in clinical out-
come measures.49
Selected Preclinical Studies
The methodology for isolating and growing chondrocytes 
for cartilage repair procedures and decisions regarding the 
dose of cells to be employed are based on many years of in 
vitro experimentation and animal studies, informed to some 
extent by the cell number density in normal articular carti-
lage. While the principal focus of this review is on the 
number of cells employed in the clinic, a brief review of 
select preclinical studies can be instructive in providing a 
context into which to place the current clinical implementa-
tion of chondrocyte cell therapy.
The seeding densities from 0.5 to 12 × 106 cells/cm2 that 
have been used in clinical studies can be viewed in the con-
text of the mean cell density found in native cartilage. One 
study found the chondrocyte density in adult human carti-
lage to be approximately 23,500 cells in a cross-sectional 
area of 1 mm2 (corresponding to 2.35 × 106 cells/cm2), 
depending on the location.50 Another study measuring den-
sity as cells per volume found approximately 24,000 cells/mm3 
only in the superficial layer and between 7,000 and 10,000 
cells/mm3 in the deeper layers.51 In addition, Stockwell 
found a mean density of 14,100 cells/mm3, with variation 
between the different joints.52 Based on in vitro experi-
ments and the above histomorphometric findings, sugges-
tions have been made that, as a rule of thumb, 3.2 × 106 
cells/cm2 should be used to fill defects in articular cartilage 
with a mean thickness of 2.3 mm.53
An important issue, as noted above, when comparing rel-
evant seeding densities among studies is the measure of the 
number of cells per surface area or per volume. While the 
term density generally refers to a per-volume value, reports 
often use this term to describe the number of cells implanted 
per surface area of the defect. In theory, the use of surface 
area best applies when it is the cell attachment to a substrate 
(e.g., the base and walls of a defect, or the struts and walls 
of a scaffold) that is being addressed. This area available for 
cell attachment is different than the articulating area encom-
passed by the defect, as assessed by the surgeon. The use of 
volume implies that the cells will display a 3-dimensional 
distribution within the defect or scaffold, perhaps as they 
settle by gravity onto each other. Calculations estimating 
the effects of cell seeding density, based on surface area or 
volume, on cartilage formation are confounded by the 
changing number of cells in the defect due to the contribu-
tions of cell proliferation, migration, and apoptosis, which 
can take effect within days after seeding.
In the absence of clinical studies relating seeding density 
to outcome, it is useful to turn to the in vitro and preclinical 
literature. Although extrapolating in vitro findings to in vivo 
behavior is generally uncertain, cell culture experiments 
investigating the effects of cell density on chondrogenesis 
can serve as useful guides to experimental parameters to be 
investigated in vivo. The importance of cell density in chon-
drogenesis was initially observed in some of the earliest 
studies of cartilage formation in vivo. Studies in embryonic 
fowl54 revealed that “mesenchyme condenses to form a 
compact mass of cells which marks the site of future carti-
lage.” “Condensation” (i.e., the increase in cell density to a 
critical mass) occurred in vivo as a result of the migration of 
previously dispersed cells55 to a central core.56 This aggre-
gation caused an increase in mesenchymal cell packing 
density55,57 without an increase in cell proliferation57,58 and 
was associated with an increase in cell-cell contacts.59,60 Of 
interest is that these in vivo observations related to the con-
densation of chondroprogenitor cells in their native 
3-dimensional matrix in vivo are reflected in in vitro find-
ings of mesenchymal stem cells (MSCs) in the “pellet” 
assay.61 In the pellet assay, MSCs in suspension are added 
to a tube and centrifuged to concentrate the cells. When 
grown in medium supplemented with dexamethasone, 
ascorbate, and transforming growth factor (TGF)–β, the cell 
concentrate forms a pellet, which undergoes further densifi-
cation by a contractile process. The condensed pellet then 
undergoes chondrogenesis.
Similar observations relating cell packing density to 
chondrogenesis have been made in studies in vitro in which 
MSCs62 and chondrocytes63,64 were seeded into sponge-
like collagen scaffolds. In the investigation of chondro-
cyte-seeded scaffolds, constructs compliant enough to 
allow contraction resulting in increased cell packing densi-
ties (~20,000 cells/mm3) displayed greater amounts of car-
tilage than constructs that displayed less contracture and, 
hence, cell density (~5,000 cells/mm3).21 Other prior stud-
ies employing cell-seeded scaffolds in vitro have shown 
an array of benefits of employing high cell densities on 
chondrogenesis, such as increased: cellular proliferation65; 
expression of cartilage-specific genes66; glycosaminogly-
can (GAG) and type II collagen content67,68; mechanical 
properties68; and cartilage-like morphology of the resulting 
tissue.65 These in vivo and in vitro findings collectively 
demonstrate the importance of cell seeding density in 
chondrogenesis.
In vitro and preclinical data on chondrocytes show con-
flicting results about the effect of increasing cell density in 
cartilage repair. In the earliest studies of in vitro chondro-
cyte culturing by Handley and Oakes, it was found that to 
maintain the chondrogenic phenotype and avoid dedifferen-
tiation, high-density cultures were necessary.69,70 In these 
studies, “high-density” chondrocyte cultures in both mono-
layer and multilayer with an initial seeding density of 
250,000 cells/cm2 showed increased proliferation and a 
much lower amount of elongated fibroblast-like cells after 
prolonged culture compared to “low-density” cultures with 
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an initial seeding density of 40,000 cells/cm2. Introducing 
biomaterials as cell carriers, similar benefits of high cell 
densities have been suggested by Francioli et al. when cul-
tured on a collagen type II scaffold, and Mahmoudifar et al. 
found that increasing the cell number on a 4.75-mm-thick 
scaffold (volume, 0.84 cm3) from 1.2 × 107 to 2.2 × 107 led 
to a significant increase in extracellular matrix (ECM) pro-
duction.71,72 Buckley et al. performed mechanical testing 
of agarose gel-embedded chondrocytes in 2 concentrations 
and found that with a fixed agarose concentration, there 
was a significant decrease in the dynamic modulus using 
40 × 106 cells/cm2 compared to 10 × 106 cells/cm2,73. 
However, other authors have found that if chondrocytes are 
packed too close together, matrix synthesis may be inhib-
ited, and thus, the synthesis rate of the ECM may decrease 
as confluence is approached.74 This is in line with another 
study that showed that a cell density of 4 × 106 cells/mL 
stimulated higher chondrogenic transcription factor (sox9) 
levels than a density of 7 × 107 cells/mL in alginate-embedded 
chondrocytes in vitro.75 In addition, an in vivo study by 
Chiang et al. found no effects of increased cell density with 
ACI in a porcine cartilage defect model.76 Although con-
flicting, most of the in vitro work demonstrates the benefits 
of high-density cultures both for human and animal studies 
in maintaining chondrocyte differentiation, and suggestions 
on the optimal seeding density based on these consider-
ations have been made.53 However, while in vitro studies 
are limited in dealing with all the issues that present in the 
clinic, these suggestions have been somewhat ignored, and 
clinical effects of using higher cell seeding densities remain 
unknown. Another complicating factor in deciding seeding 
density is that implanted cells in a periosteum-covered 
defect have been found to be unequally dispersed due to 
gravity, which results in a heterogeneous chondrocyte den-
sity in the defect after implantation.77
Advantages of a lower cell density for cartilage repair 
procedures include smaller biopsy size and decreased cul-
ture time, and although donor site morbidity relative to 
biopsy size is still controversial, there is no question that 
shortening of culture time will decrease the costs of in vitro 
growth of the cells. Another potentially favorable conse-
quence of shortening the culture time is the limitation of the 
dedifferentiation of the chondrocytes, marked by the shift in 
collagen type from II to I, and the decrease in sox9 expres-
sion, which is seen in their prolonged culture in mono-
layer.78,79 However, while not yet fully understood, it has 
been proposed that these changes with culture time are not 
a result of actual dedifferentiation and that redifferentiation 
of these chondrocytes can be obtained by different interven-
tions including reimplantation.80-83
Several factors influence the cells during in vitro culture 
such as culture time, culture environment (oxygen, culture 
medium, growth factors, surface), seeding density, and 
quality of the harvested chondrocytes.21-23,75,84,85 Thus, 
implementing these factors for the in vitro culture can 
influence the quality and the differentiated state of the 
implanted cells even in low-density cultures.86 In addition, 
clinical factors such as patient selection, patient and sur-
geon variability, and rehabilitation also contribute signifi-
cantly to the outcome.
Discussion
No clinical studies have specifically investigated the effect 
of cell seeding density on the amount and type of reparative 
tissue and clinical outcome, and the preclinical data remain 
inconclusive in determining to what extent cartilage repair 
is affected by seeding density. The optimal cell seeding 
density may vary with seeding efficiency (i.e., the number 
of cells that survive the implantation process), distribution 
of cells in the defect, and the use of cell carriers/scaffolds 
as opposed to injection of a suspension under a covering 
membrane. Investigation of the specific influence of cell 
density on the clinical outcome of scaffold-supported ACI 
treatment is also confounded by the contribution of both 
chemical and physical properties of the scaffold, including 
surface area and pore characteristics.87 Hence, the optimal 
cell density may also be scaffold dependent.
Regulating the cell concentration in the final cell prod-
uct, consisting of cultured cells in a suspension, to deliver a 
specific number of cells for a particular defect is important 
and relies on the surgeon’s estimate of the volume of the 
defect. Thus, if the surgeon wants to implant a minimum of 
12 × 106 cells in a 4-cm2 defect with an average depth of 
2 mm, the cell concentration in the suspension should be at 
least 15 × 106 cells/mL. This issue is of importance for both 
the surgeon as well as the cell culture company.
The clinical indications of ACI-related procedures are 
continuously being debated, and some argue that the evi-
dence for treating these patients is too sparse.10 While the 
aim should always be improvement of the patients’ joint 
function and quality of life, only a limited number of studies 
integrate several objective outcome measures such as MRI, 
indentometry, and histology, which are useful in correlating 
the biological response to our interventions.88,89
When reviewing the clinical literature, it becomes evi-
dent that few studies report the cell seeding density that was 
employed. In addition, comparing the outcome of cartilage 
repair treatments is also hampered by the selective use of 
the many different clinical functional outcome measures. 
There is no evidence that patients treated with chondrocyte 
implantations in a high density have better outcomes than 
when treated with low-density ACI. Hence, despite the ten-
dency in the preclinical literature toward favoring high den-
sities, the clinical effect is unknown. In addition, the cells 
are not equally distributed within the defect, and thus, some 
parts of the treated defect might have high densities and 
other parts low densities. Future preclinical studies and 
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clinical investigations in particular are indeed needed to 
more substantially investigate proper cell seeding densities 
with direct comparisons of seeding densities with objective 
evaluation measurements such as histology and MRI. 
Future findings could potentially limit the in vitro culture 
time and biopsy size and provide a better clinical outcome.
Conclusion
In the absence of systematic evaluations of the effects of 
cell density and clinical outcome, many clinicians continue 
to use 1 to 2 × 106 chondrocytes/cm2, which, despite its lack 
of evidence and the fact that most in vitro studies point 
toward benefits of higher densities, has been associated 
with favorable clinical outcomes and also nearly approxi-
mates the densities found in native adult articular cartilage.
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